DHAP (chemotherapy)
From Infogalactic: the planetary knowledge core
DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory Non-Hodgkin lymphoma and Hodgkin disease.[1] It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplant. In combination with anti-CD20 monoclonal antibody Rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R.
[R]-DHAP regimen consists of:
- Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20
- (D)examethasone, a glucocorticoid hormone
- (H)igh-dose (A)ra-C - cytarabine, an antimetabolite;
- (P)latinol (cisplatin), a platinum-based antineoplastic agent with an alkylating mechanism;
Dosing regimen
Drug | Dose | Mode | Days |
---|---|---|---|
(R)ituximab | 375 mg/m2 | IV infusion | Day 0 |
(D)examethasone | 40 mg | PO qd | Days 1-4 |
(H)igh-dose Ara-C - cytarabine | 2000 mg/m2 | IV infusion over 2 hrs | Day 2, every 12 hours |
(P)latinol (cisplatin) | 100 mg/m2 | IV infusion over 24 hrs | Day 1 |